Synthetic Biohybrids of Red Blood Cells and Cascaded‐Enzymes@ Metal–Organic Frameworks for Hyperuricemia Treatment

• Published in: Advanced science 2024-02, Vol.11 (5), p.e2305126-n/a
• Main Authors: Li, Zeyu, Xue, Liecong, Yang, Junxian, Wuttke, Stefan, He, Peiying, Lei, Chuanyi, Yang, Haowei, Zhou, Liang, Cao, Jiangfan, Sinelshchikova, Anna, Zheng, Guansheng, Guo, Jimin, Lin, Jiangguo, Lei, Qi, Brinker, C. Jeffrey, Liu, Kaisheng, Zhu, Wei
• Format: Article
• Language: English
• Subjects: biohybrid materials; Catalysis; enzyme; Enzymes; Fourier transforms; hyperuricemia; Ligands; Metabolism; Metal‐organic Frameworks; Nanoparticles; red blood cells; Spectrum analysis; Uric acid
• ISSN: 2198-3844; 2198-3844
• DOI: 10.1002/advs.202305126

Hyperuricemia, caused by an imbalance between the rates of production and excretion of uric acid (UA), may greatly increase the mortality rates in patients with cardiovascular and cerebrovascular diseases. Herein, for fast‐acting and long‐lasting hyperuricemia treatment, armored red blood cell (RBC) biohybrids, integrated RBCs with proximal, cascaded‐enzymes of urate oxidase (UOX) and catalase (CAT) encapsulated within ZIF‐8 framework‐based nanoparticles, have been fabricated based on a super‐assembly approach. Each component is crucial for hyperuricemia treatment: 1) RBCs significantly increase the circulation time of nanoparticles; 2) ZIF‐8 nanoparticles‐based superstructure greatly enhances RBCs resistance against external stressors while preserving native RBC properties (such as oxygen carrying capability); 3) the ZIF‐8 scaffold protects the encapsulated enzymes from enzymatic degradation; 4) no physical barrier exists for urate diffusion, and thus allow fast degradation of UA in blood and neutralizes the toxic by‐product H2O2. In vivo results demonstrate that the biohybrids can effectively normalize the UA level of an acute hyperuricemia mouse model within 2 h and possess a longer elimination half‐life (49.7 ± 4.9 h). They anticipate that their simple and general method that combines functional nanomaterials with living cell carriers will be a starting point for the development of innovative drug delivery systems. Armored red blood cell (RBC) biohybrids, integrated RBCs with proximal, cascaded‐enzymes of urate oxidase and catalase encapsulated within ZIF‐8 framework‐based nanoparticles, have been fabricated for fast‐acting and long‐lasting urate‐lowering therapy. RBC biohybrids could normalize the UA level of acute hyperuricemia model mice within 2 h, and possessed an elimination half‐life of 49.7 ± 4.9 h, which is over thrice longer than that of free UOX, representing an innovative drug carrier for hyperuricemia treatment.